KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Long-Term Deferred Tax (2020 - 2025)

Pacira BioSciences has reported Long-Term Deferred Tax over the past 6 years, most recently at $123.9 million for Q4 2025.

  • Quarterly results put Long-Term Deferred Tax at $123.9 million for Q4 2025, down 5.0% from a year ago — trailing twelve months through Dec 2025 was $123.9 million (down 5.0% YoY), and the annual figure for FY2025 was $123.9 million, down 5.0%.
  • Long-Term Deferred Tax for Q4 2025 was $123.9 million at Pacira BioSciences, up from $120.2 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for PCRX hit a ceiling of $169.3 million in Q1 2022 and a floor of $93.3 million in Q3 2021.
  • Median Long-Term Deferred Tax over the past 5 years was $138.1 million (2024), compared with a mean of $138.2 million.
  • Biggest five-year swings in Long-Term Deferred Tax: soared 69.52% in 2022 and later fell 15.82% in 2024.
  • Pacira BioSciences' Long-Term Deferred Tax stood at $153.4 million in 2021, then grew by 4.53% to $160.3 million in 2022, then decreased by 9.87% to $144.5 million in 2023, then fell by 9.77% to $130.4 million in 2024, then fell by 5.0% to $123.9 million in 2025.
  • The last three reported values for Long-Term Deferred Tax were $123.9 million (Q4 2025), $120.2 million (Q3 2025), and $128.3 million (Q2 2025) per Business Quant data.